CFG920 is a Steroid 17-alpha-hydroxylase inhibitor originated by Novartis. It has potential antiandrogen and antineoplastic activities. It may inhibit cell proliferation of androgen-dependent tumor cells. In Jan 2013, Phase-I clinical trials in Prostate cancer in Spain was on-going, but now clinical trials for Prostate cancer is discontinued.